Preclinical studies have shown promising anticancer activity from TNO155 combined with inhibitors of EGFR, MEK, ERK, CDK4/6, or KRAS-G12C and anti–PD-1 antibodies in xenograft models of NSCLC or CRC cells [116]. Here, KRAS is linked to non-small cell lung carcinoma.